MARC details
000 -LEADER |
fixed length control field |
06176naaaa2201525uu 4500 |
001 - CONTROL NUMBER |
control field |
https://directory.doabooks.org/handle/20.500.12854/87543 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20220714201349.0 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
books978-3-0365-4489-2 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9783036544908 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9783036544892 |
024 7# - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.3390/books978-3-0365-4489-2 |
Terms of availability |
doi |
041 0# - LANGUAGE CODE |
Language code of text/sound track or separate title |
English |
042 ## - AUTHENTICATION CODE |
Authentication code |
dc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
TB |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
TBX |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
TGM |
Source |
bicssc |
100 1# - MAIN ENTRY--PERSONAL NAME |
Personal name |
Tagit, Oya |
Relator code |
edt |
9 (RLIN) |
1628618 |
245 10 - TITLE STATEMENT |
Title |
Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
Place of publication, distribution, etc |
Basel |
Name of publisher, distributor, etc |
MDPI - Multidisciplinary Digital Publishing Institute |
Date of publication, distribution, etc |
2022 |
300 ## - PHYSICAL DESCRIPTION |
Extent |
1 electronic resource (296 p.) |
506 0# - RESTRICTIONS ON ACCESS NOTE |
Terms governing access |
Open Access |
Source of term |
star |
Standardized terminology for access restriction |
Unrestricted online access |
520 ## - SUMMARY, ETC. |
Summary, etc |
Nanomedicine is among the most promising emerging fields that can provide innovative and radical solutions to unmet needs in pharmaceutical formulation development. Encapsulation of active pharmaceutical ingredients within nano-size carriers offers several benefits, namely, protection of the therapeutic agents from degradation, their increased solubility and bioavailability, improved pharmacokinetics, reduced toxicity, enhanced therapeutic efficacy, decreased drug immunogenicity, targeted delivery, and simultaneous imaging and treatment options with a single system.Poly(lactide-co-glycolide) (PLGA) is one of the most commonly used polymers in nanomedicine formulations due to its excellent biocompatibility, tunable degradation characteristics, and high versatility. Furthermore, PLGA is approved by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for use in pharmaceutical products. Nanomedicines based on PLGA nanoparticles can offer tremendous opportunities in the diagnosis, monitoring, and treatment of various diseases.This Special Issue aims to focus on the bench-to-bedside development of PLGA nanoparticles including (but not limited to) design, development, physicochemical characterization, scale-up production, efficacy and safety assessment, and biodistribution studies of these nanomedicine formulations. |
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE |
Terms governing use and reproduction |
Creative Commons |
-- |
https://creativecommons.org/licenses/by/4.0/ |
-- |
cc |
-- |
https://creativecommons.org/licenses/by/4.0/ |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Technology: general issues |
Source of heading or term |
bicssc |
9 (RLIN) |
928609 |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
History of engineering & technology |
Source of heading or term |
bicssc |
9 (RLIN) |
1129967 |
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Materials science |
Source of heading or term |
bicssc |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
poly(lactic-co-glycolic acid) (PLGA) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
blood-brain barrier (BBB) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
current Good Manufacturing Practice (cGMP) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Food and Drug Administration (FDA) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanotechnology |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
PLGA nanoparticles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
neurodegenerative diseases |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
drug delivery |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
central nervous system |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
neuroprotective drugs |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
fluorescent labeling |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
DiI |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
coumarin 6 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
rhodamine 123 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Cy5.5 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
quantum yield |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
brightness |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
stability of fluorescent label |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
confocal microscopy |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
intracellular internalization |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
in vivo neuroimaging |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
double-emulsion method |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
dry powder inhalation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
antigen release |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
porous PLGA particles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
microfluidics |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
methotrexate |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
chitosan |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
PLA/PLGA |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
sustained release |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
micro-implant |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
animal model |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
minimally invasive |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
drug delivery system |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanoparticles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
poly (lactic-co-glycolic acid) (PLGA) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
microfluidic |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
pharmacokinetics (PK) and biodistribution |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
atorvastatin calcium |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
poly(lactide-co-glycolide) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
polymeric nanoparticles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
carrageenan induced inflammation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
anti-inflammatory |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
radiolabeled nanoparticles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nuclear medicine |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
photothermal therapy |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
phthalocyanine |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
SKOVip-kat |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Katushka |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
TurboFP635 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
JO-4 |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
PLGA |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
orthotopic tumors |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
3D culture |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
spheroids |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
poly(lactic-co-glycolic acid) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanomedicine |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
scale-up manufacturing |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
clinical translation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
inline sonication |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
tangential flow filtration |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
lyophilization |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
downstream processing |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
H. pylori |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
design of experiments |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
poly(lactic-co-glycolic) acid |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
size |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
cancer |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
chemoimmunotherapy |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
immunogenic cell death |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
immune checkpoint blockade |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
PNA5 glycopeptide |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
mas receptor |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
angiotensin |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
PLGA diblock copolymer |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
ester and acid-end capped |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
double emulsion solvent evaporation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
biocompatible |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
biodegradable |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
cardiovascular |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
nanoparticle |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
solid-state characterization |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
in vitro |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
drug release kinetics modeling |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
PEGylation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
amine |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
emulsion |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
polyvinyl alcohol (PVA) |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Pluronic triblock copolymer |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
trehalose |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
sucrose |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Indomethacin |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
solvents |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
stabilizers |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
morphology |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
particle-size |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
encapsulation |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
drug release |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
cytotoxicity |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Tagit, Oya |
Relator code |
oth |
9 (RLIN) |
1628618 |
856 40 - ELECTRONIC LOCATION AND ACCESS |
Host name |
www.oapen.org |
Uniform Resource Identifier |
<a href="https://mdpi.com/books/pdfview/book/5741">https://mdpi.com/books/pdfview/book/5741</a> |
-- |
0 |
Public note |
DOAB: download the publication |
856 40 - ELECTRONIC LOCATION AND ACCESS |
Host name |
www.oapen.org |
Uniform Resource Identifier |
<a href="https://directory.doabooks.org/handle/20.500.12854/87543">https://directory.doabooks.org/handle/20.500.12854/87543</a> |
-- |
0 |
Public note |
DOAB: description of the publication |